Advertisement

Recent considerations in nonsteroidal anti-inflammatory drug gastropathy

  • Gurkirpal Singh
    Correspondence
    Requests for reprints should be addressed to Gurkirpal Singh, MD, Stanford University School of Medicine, Department of Medicine, Division of Immunology and Rheumatology, 1000 Welch Road, Suite 203, Palo Alto, California 94303
    Affiliations
    Department of Medicine, Division of Immunology and Rheumatology, and the ARAMIS Postmarketing Surveillance Program, Stanford University of Medicine, Palo Alto, California, USA
    Search for articles by this author

      Abstract

      Conservative calculations estimate that approximately 107,000 patients are hospitalized annually for nonsteroidal anti-inflammatory drug (NSAID)-related gastrointestinal (GI) complications and at least 16,500 NSAID-related deaths occur each year among arthritis patients alone. The figures for all NSAID users would be overwhelming, yet the scope of this problem is generally under-appreciated. The Arthritis, Rheumatism, and Aging Medical Information System (ARAMIS) Post-Marketing Surveillance Program (PMS) has prospectively followed patient status and outcomes, drug side effects, and the economic impact of illness for >11,000 arthritis patients at 8 participating institutions in the United States and Canada. Analysis of these data indicates that: (1) osteoarthritis (OA) and rheumatoid arthritis (RA) patients are 2.5–5.5 times more likely than the general population to be hospitalized for NSAID-related GI events; (2) the absolute risk for serious NSAID-related GI toxicity remains constant and the cumulative risk increases over time; (3) there are no reliable warning signals— >80% of patients with serious GI complications had no prior GI symptoms; (4) independent risk factors for serious GI events were age, prednisone use, NSAID dose, disability level, and previous NSAID-induced GI symptoms; and (5) antacids and H2 antagonists do not prevent NSAID-induced gastric ulcers, and high-risk NSAID users who take gastro-protective drugs are more likely to have serious GI complications than patients not taking such medications. Currently, limiting NSAID use is the only way to decrease the risk of NSAID-related GI events. Ongoing ARAMIS research is aimed at developing a simple point-score system for estimating individual risks of developing serious NSAID-related GI complications.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Singh G
        • Ramey D.R
        • Morfeld D
        • et al.
        Gastrointestinal tract complications of non-steroidal anti-inflammatory drug treatment in rheumatoid arthritis—A prospective observational cohort study.
        Arch Intern Med. 1996; 156: 1530-1536
        • Fries J.F
        • McShane D.J
        ARAMIS (The American Rheumatism Association Medical Information System).
        West J Med. 1986; 145: 798-804
        • Fries J.F
        • Ramey D.R
        • Singh G
        • et al.
        A reevaluation of aspirin therapy in rheumatoid arthritis.
        Arch Intern Med. 1993; 153: 2465-2471
        • Singh G
        • Fries J.F
        • Spitz P.W
        • et al.
        Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective (Abstr.).
        Arthritis Rheum. 1989; 32: 837-843
        • Singh G
        • Fries J.F
        • Williams C.A
        • et al.
        Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis.
        J Rheumatol. 1991; 18: 188-194
        • Fries J.F
        • Spitz P.W
        • Kraines R.G
        • Holman H.R
        Measurement of patient outcome in arthritis.
        Arthritis Rheum. 1980; 23: 137-145
        • Ramey D.R
        • Singh G.S
        • Fries J.F
        The Health Assessment Questionnaire 1995.
        in: Spilker B Pharmacoeconomics and Quality of Life in Clinical Trials. 2nd ed. Lippincott-Raven, Philadelphia1996: 227-237
        • Buchanan W.W
        • Brooks P.M
        Prediction of organ system toxicity with anti-rheumatic drug therapy.
        in: Bellamy N Prognosis in the Rheumatic Diseases. Kluwer Academic Publishers, Boston1991: 403-450
        • Brooks P.M
        • Day R.O
        Nonsteroidal antiinflammatory drugs—differences and similarities.
        N Engl J Med. 1991; 324: 1716-1725
        • Hardin J.G
        • Longenecker G.L
        Handbook of Drug Therapy in Rheumatic Disease. Pharmacology and Clinical Aspects. Little, Brown and Company, Boston1992
        • Paulus H.E
        Nonsteroidal Anti-inflammatory Drugs.
        in: Kelly W.N Harris Jr, E.D Ruddy S Sledge C.B Textbook of Rheumatology. WB Saunders Company, Philadelphia1989: 765-791
        • Ehsanullah R.S
        • Page M.C
        • Tildesley G
        • Wood J.R
        Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs.
        BMJ. 1988; 297: 1017-1021
        • Caruso I
        • Bianchi Porro G
        Gastroscopic evaluation of antiinflammatory agents.
        BMJ. 1980; 280: 75-78
        • McCarthy D.M
        Nonsteroidal antiinflammatory drug induced ulcers.
        Gastroenterology. 1989; 96: 662-674
        • Gabriel S.E
        • Jaakkimainen L
        • Bombardier C
        The cost-effectiveness of misoprostol for nonsteroidal antiinflammatory drug-associated adverse gastrointestinal events.
        Arthritis Rheum. 1993; 36: 447-459
        • Gabriel S.E
        • Jaakkimainen L
        • Bombardier C
        Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis.
        Ann Intern Med. 1991; 115: 787-796
        • Paulus H.E
        Government affairs. FDA Arthritis Advisory Committee meeting: risks of agranulocytosis/aplastic anemia, flank pain, and adverse gastrointestinal effects with the use of nonsteroidal antiinflammatory drugs.
        Arthritis Rheum. 1987; 30: 593-595
        • Silverstein F.E
        • Graham D.Y
        • Senior J.R
        • et al.
        Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial.
        Ann Intern Med. 1995; 123: 241-249
        • Langman M.J
        • Weil J
        • Wainwright P
        • et al.
        Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs.
        Lancet. 1994; 343: 1075-1078
        • Garcia Rodriguez L.A
        • Jick H
        Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs.
        Lancet. 1994; 343: 769-772
        • Singh G
        • Ramey D.R
        • Terry R
        • Triadafilopoulus G
        NSAID-related effects on the GI tract: an ever widening spectrum (Abstr.).
        Gastroenterology. 1997; 112: A42
        • Griffin M.R
        • Piper J.M
        • Daugherty J.R
        • et al.
        Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons.
        Ann Intern Med. 1991; 114: 257-263
        • Armstrong C.P
        • Blower A.L
        Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulcerations.
        Gut. 1987; 28: 527-532
      1. National Center for Health Statistics. GMWKI: total deaths for each cause by 5-year age groups, United States, 1994 (unpublished data from NCHS website data warehouse). Hyattsville, MD: Public Health Service, 1997.

        • Larkai E.N
        • Smith J.L
        • Lidsky M.D
        Gastroduodenal mucosa and dyspeptic symptoms in arthritis patients during chronic nonsteroidal anti-inflammatory drug use.
        Am J Gastroenterol. 1987; 82: 1153-1158
        • Polisson R
        Nonsteroidal anti-inflammatory drugs.
        Am J Med. 1996; 100: 31S-36S
        • Lichtenstein D.R
        • Syngal S
        • Wolfe M.M
        Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. The double-edged sword.
        Arthritis Rheum. 1995; 38: 5-18
        • Bjorkman D.J
        Nonsteroidal anti-inflammatory drug-induced gastrointestinal injury.
        Am J Med. 1996; 101: 25S-32S
        • Longstreth G.F
        Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage.
        Am J Gastroenterol. 1995; 90: 206-210
        • Greene J.M
        • Winickoff R.N
        Cost-conscious prescribing of nonsteroidal anti-inflammatory drugs for adults with arthritis. A review and suggestions.
        Arch Intern Med. 1992; 152: 1995-2002
        • Hallas J
        • Lauritsen J
        • Villadsen H.D
        • Gram L.F
        Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates.
        Scand J Gastroenterol. 1995; 30: 438-444
        • Hochain P
        • Berkelmans I
        • Czernichow P
        • et al.
        Which patients taking non-aspirin nonsteroidal anti-inflammatory drugs bleed? A case-control study.
        Eur J Gastroenterol Hepatol. 1995; 7: 419-426
        • Piper J.M
        • Ray W.A
        • Daugherty J.R
        • et al.
        Corticosteroid use and peptic ulcer disease.
        Ann Intern Med. 1991; 114: 735-740
        • Shorr R.I
        • Ray W.A
        • Daugherty J.R
        • et al.
        Concurrent use of non-steroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease.
        Arch Intern Med. 1993; 153: 1665-1670
        • Lanza F.L
        • Royer G.L
        • Nelson R.S
        • et al.
        A comparative endoscopic evaluation of damaging effects of nonsteroidal antiinflammatory agents on the gastric and duodenal mucosa.
        Am J Gastroenterol. 1981; 75: 17-21
        • Lanza F.L
        • Nelson R.S
        • Greenberg B.P
        Effects of fenbufen, indomethacin, naproxen and placebo on gastric mucosa of normal volunteers.
        Am J Med. 1983; 75: 75-79
        • Lanza F.L
        Endoscopic studies of gastric and duodenal injury after the use of ibuprofen, aspirin, and other nonsteroidal antiinflammatory drugs.
        Am J Med. 1984; 77: 19-24
        • Lanza F
        • Rack M.F
        • Lyn M
        • et al.
        An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa.
        J Rheumatol. 1987; 14: 338-341
        • Lanza F
        • Rack M.F
        • Doucette M
        • et al.
        An endoscopic comparison of the gastroduodenal injury seen with salsalate and naproxen.
        J Rheumatol. 1989; 16: 1570-1574
        • Carson J.L
        • Strom B.L
        • Morse M.L
        • et al.
        The relative gastrointestinal toxicity of the nonsteroidal anti-inflammatory drugs.
        Arch Intern Med. 1987; 147: 1054-1059
        • Fries J.F
        • Spitz P.W
        • Williams C.A
        • et al.
        A toxicity index for comparison of side effects among different drugs.
        Arthritis Rheum. 1990; 33: 121-130
        • Fries J.F
        • Williams C.A
        • Block D.A
        The relative toxicity of non-steroidal anti-inflammatory drugs.
        Arthritis Rheum. 1991; 34: 1353-1360
        • Fries J.F
        • Williams C.A
        • Ramey D
        • Bloch D.A
        The relative toxicity of disease modifying antirheumatic drugs (DMARDs).
        Arthritis Rheum. 1993; 36: 297-306
        • Singh G
        • Williams C.A
        • Ramey D.R
        • Fries J.F
        A toxicity index for comparison of gastrointestinal toxicity of non-steroidal anti-inflammatory drugs (NSAIDs) (Abstr.).
        Arthritis Rheum. 1993; 36: S178
        • Singh G
        • Ramey D.R
        • Morfeld D
        • Fries J.F
        Comparative toxicity of non-steroidal anti-inflammatory agents.
        Pharmacol Ther. 1994; 62: 1750-1791
        • Robinson M.G
        • Griffin Jr, J.W
        • Bowers J
        • et al.
        Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal anti-inflammatory drugs.
        Dig Dis Sci. 1989; 34: 424-428
        • Oddsson E
        • Gudjonsson H
        • Thjodleifsson B
        Comparison between ranitidine and omeprazole for protection against gastroduodenal damage caused by naproxen.
        Scand J Gastroenterol. 1992; 27: 1045-1048
        • Avorn J
        • Solomon D
        • Levin R
        • Lo J
        Epidemiologic analysis of prophylactic drug use and NSAID gastropathy (Abstr.).
        Arthritis Rheum. 1996; 39: S165